Skip to content

MAZE MAZE US — Revenue

Similar metrics at other companies

Theravance Biopharma logo
TBPHUS — Revenue
$18.74M+16.4%
Iovance Biotherapeutics, Inc. logo
IOVAUS — Revenue
$70.47M+45.2%
ARS Pharmaceuticals, Inc. logo
SPRYUS — Revenue
$17.45M+125%
PTC Therapeutics logo
PTCTUS — Revenue
$136.52M+186%
HTF
HTFLUS — Revenue
$48.99M+42.8%
Eastman Kodak Company logo
KODKUS — Revenue
$134M+12.6%

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$26.6M+25.0%
Net income-$24.2M+26.2%
EPS (diluted)-$0.45+60.9%

Balance sheet

See full
Cash & equivalents$198.8M-32.5%
Total debt$61.2M+137%
Total equity$341.7M+17.0%
Total assets$419.7M+26.1%

Cash flow

See full
Operating cash flow-$39.1M-32.5%
CapEx$93.0K-68.9%
Free cash flow-$39.2M-31.5%

Valuation

See full
Market cap$1.48B+201%
Enterprise value$1.34B
P/S7.9×

Profitability

See full
Operating margin-71.5%
Net margin-65.4%
FCF margin-65.1%

Returns & leverage

See full
Return on equity-38.7%
Debt / equity0.2×+0.1×
Current ratio17.9×+1.8×

Where this comes from

Reported directly by MAZE in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: MAZE’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about MAZE's us — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MAZE's US — revenue?
MAZE (MAZE) reported US — revenue of $20M in Q1 2026.
What does US — revenue mean?
This metric represents the total gross revenue generated from commercial activities, licensing agreements, or service contracts within the United States geographic segment, excluding any collected sales taxes. For a clinical-stage biopharmaceutical company, this figure typically reflects the absence of commercialized product sales or the recognition of milestone payments and research collaborations. It serves as a primary indicator of the company's ability to monetize its research and development pipeline within the domestic market.